Compare ACEL & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | IVA |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.7M | 804.2M |
| IPO Year | N/A | 2020 |
| Metric | ACEL | IVA |
|---|---|---|
| Price | $11.60 | $6.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.00 | ★ $16.00 |
| AVG Volume (30 Days) | 413.6K | ★ 414.1K |
| Earning Date | 02-26-2026 | 09-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $1,307,029,000.00 | $19,929,536.00 |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | $23.05 | ★ N/A |
| Revenue Growth | ★ 7.97 | N/A |
| 52 Week Low | $9.02 | $2.11 |
| 52 Week High | $13.28 | $7.98 |
| Indicator | ACEL | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 78.22 |
| Support Level | $11.29 | $4.48 |
| Resistance Level | $11.87 | $5.17 |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | -0.03 | 0.19 |
| Stochastic Oscillator | 55.00 | 94.28 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.